A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy (NCT06793709)
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
Osservazionale
Fase non elencata
#Eisai Trial Site 1
Sponsor: Eisai
Ultimo Aggiornamento: 27 febbraio 2026
Avviso - Le informazioni provengono da registri pubblici e potrebbero non riflettere i cambiamenti in tempo reale presso il centro locale.
The primary purpose of this study is to investigate the safety of Tasfygo.
1. Participants with unresectable biliary tract cancer with FGFR2 fusion gene positivity who are naïve to Tasfygo tablet and progressed after chemotherapy.
Criteri di Esclusione
Not applicable.
Pensi che questo studio appaia erroneamente?
Dettagli del Disegno
AllocazioneN/A
Modello di InterventoN/A
MascheramentoN/A
Numero da Arruolare60
Bracci e Interventi
Bracci
Interventi
Tipo: N/A
Descrizione:
Interventi:
No Intervention
Misure di Esito
Misure di Esito Primarie
Number of Participants With Adverse Drug ReactionsUp to 1 year
Misure di Esito Secondarie
Percentage of Participants With Best Overall Response (BOR) Based on Physician's AssessmentUp to 1 year